{
    "info": {
        "nct_id": "NCT03781986",
        "official_title": "A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma",
        "inclusion_criteria": "* Histologically documented malignant salivary gland cancers (including secretory glands of the aerodigestive tract) with or without metastases, not amenable to curative treatment; or there is documentation of patient refusal of curative treatment.\n* Previous mutational testing with no evidence of a p53 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\n* Presence of measurable disease by CT scan per RECIST v1.1 with ≥ 20% increase in tumor burden in the preceding 12 months\n* Life expectancy of ≥12 weeks\n* Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Patients must be able to take oral medication without breaking/opening, crushing, dissolving, or chewing capsules\n* Adequate organ and marrow function obtained ≤ 2 weeks prior to enrollment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with MDM2 inhibitors\n* Patients are not eligible if they have received any systemic anti-cancer therapy (including chemotherapy and/or hormone therapy) for salivary gland cancer within 4 weeks of the start of study therapy\n* Patients are not eligible if they have received any of the following within 4 weeks of the start of study therapy: live vaccines, antiretroviral drugs\n* Progressive disease within 6 months of the last dose of platinum-based chemotherapy\n* Patients with active brain metastases are excluded because of unknown penetration into the central nervous system (CNS). A confirmatory scan for asymptomatic patients is not required. Patients with a history of treated CNS metastases are eligible provided they meet all of the following criteria: disease outside the CNS is present, no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and enrollment, and recovery from significant (Grade ≥ 3) acute toxicity.\n* A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment\n* Patients (male and female) having procreative potential who are not willing or not able to use 2 adequate methods of contraception or practicing abstinence during the study and for 90 days following their last dose of treatment\n* Women who are pregnant or breast-feeding",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of ≥12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of ≥12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous mutational testing with no evidence of a p53 mutation",
            "criterions": [
                {
                    "exact_snippets": "Previous mutational testing with no evidence of a p53 mutation",
                    "criterion": "p53 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented malignant salivary gland cancers (including secretory glands of the aerodigestive tract) with or without metastases, not amenable to curative treatment; or there is documentation of patient refusal of curative treatment.",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented malignant salivary gland cancers (including secretory glands of the aerodigestive tract)",
                    "criterion": "malignant salivary gland cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without metastases",
                    "criterion": "metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "with or without"
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to curative treatment",
                    "criterion": "curative treatment amenability",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "documentation of patient refusal of curative treatment",
                    "criterion": "patient refusal of curative treatment",
                    "requirements": [
                        {
                            "requirement_type": "refusal documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function obtained ≤ 2 weeks prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained ≤ 2 weeks prior to enrollment",
                    "criterion": "organ and marrow function assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "time since assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to take oral medication without breaking/opening, crushing, dissolving, or chewing capsules",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to take oral medication without breaking/opening, crushing, dissolving, or chewing capsules",
                    "criterion": "ability to take oral medication (capsules)",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method of ingestion",
                            "expected_value": "without breaking/opening, crushing, dissolving, or chewing capsules"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of measurable disease by CT scan per RECIST v1.1 with ≥ 20% increase in tumor burden in the preceding 12 months",
            "criterions": [
                {
                    "exact_snippets": "Presence of measurable disease by CT scan per RECIST v1.1",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "CT scan"
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 20% increase in tumor burden in the preceding 12 months",
                    "criterion": "tumor burden",
                    "requirements": [
                        {
                            "requirement_type": "change",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "preceding 12 months"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Signed and dated informed consent document",
                    "criterion": "informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment",
                    "criterion": "patient (or legally acceptable representative) informed of trial aspects",
                    "requirements": [
                        {
                            "requirement_type": "informed_of_pertinent_aspects",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures",
            "criterions": [
                {
                    "exact_snippets": "Willingness ... to comply with scheduled visits",
                    "criterion": "scheduled visits compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability to comply with scheduled visits",
                    "criterion": "scheduled visits compliance",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness ... to comply with ... treatment plans",
                    "criterion": "treatment plan compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability to comply with ... treatment plans",
                    "criterion": "treatment plan compliance",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness ... to comply with ... laboratory tests",
                    "criterion": "laboratory test compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability to comply with ... laboratory tests",
                    "criterion": "laboratory test compliance",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness ... to comply with ... other study procedures",
                    "criterion": "other study procedure compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability to comply with ... other study procedures",
                    "criterion": "other study procedure compliance",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with active brain metastases are excluded because of unknown penetration into the central nervous system (CNS). A confirmatory scan for asymptomatic patients is not required. Patients with a history of treated CNS metastases are eligible provided they meet all of the following criteria: disease outside the CNS is present, no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and enrollment, and recovery from significant (Grade ≥ 3) acute toxicity.",
            "criterions": [
                {
                    "exact_snippets": "Patients with active brain metastases are excluded",
                    "criterion": "active brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a history of treated CNS metastases are eligible provided they meet all of the following criteria: disease outside the CNS is present",
                    "criterion": "disease outside the CNS",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no clinical evidence of progression since completion of CNS-directed therapy",
                    "criterion": "progression of CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "clinical evidence of progression since completion of CNS-directed therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "minimum 4 weeks between completion of radiotherapy and enrollment",
                    "criterion": "interval between completion of radiotherapy and enrollment",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "recovery from significant (Grade ≥ 3) acute toxicity",
                    "criterion": "recovery from significant (Grade ≥ 3) acute toxicity",
                    "requirements": [
                        {
                            "requirement_type": "recovery from acute toxicity (Grade ≥ 3)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment",
            "criterions": [
                {
                    "exact_snippets": "serious uncontrolled medical disorder",
                    "criterion": "medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with MDM2 inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with MDM2 inhibitors",
                    "criterion": "prior treatment with MDM2 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients are not eligible if they have received any of the following within 4 weeks of the start of study therapy: live vaccines, antiretroviral drugs",
            "criterions": [
                {
                    "exact_snippets": "received any of the following within 4 weeks of the start of study therapy: live vaccines",
                    "criterion": "live vaccines",
                    "requirements": [
                        {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "received any of the following within 4 weeks of the start of study therapy: ... antiretroviral drugs",
                    "criterion": "antiretroviral drugs",
                    "requirements": [
                        {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or breast-feeding",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... breast-feeding",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "breast-feeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressive disease within 6 months of the last dose of platinum-based chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Progressive disease within 6 months of the last dose of platinum-based chemotherapy",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to platinum-based chemotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": "platinum-based chemotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients are not eligible if they have received any systemic anti-cancer therapy (including chemotherapy and/or hormone therapy) for salivary gland cancer within 4 weeks of the start of study therapy",
            "criterions": [
                {
                    "exact_snippets": "received any systemic anti-cancer therapy (including chemotherapy and/or hormone therapy) for salivary gland cancer within 4 weeks of the start of study therapy",
                    "criterion": "systemic anti-cancer therapy for salivary gland cancer",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients (male and female) having procreative potential who are not willing or not able to use 2 adequate methods of contraception or practicing abstinence during the study and for 90 days following their last dose of treatment",
            "criterions": [
                {
                    "exact_snippets": "Patients (male and female) having procreative potential",
                    "criterion": "procreative potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not willing or not able to use 2 adequate methods of contraception or practicing abstinence during the study and for 90 days following their last dose of treatment",
                    "criterion": "contraception or abstinence use",
                    "requirements": [
                        {
                            "requirement_type": "willingness or ability to use contraception or abstinence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}